{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:22:48Z","timestamp":1768090968498,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,10]]},"DOI":"10.7759\/cureus.101249","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:24:53Z","timestamp":1768076693000},"source":"Crossref","is-referenced-by-count":0,"title":["Syndrome of Inappropriate Antidiuretic Hormone Secretion and Thrombotic Microangiopathy as Paraneoplastic Syndromes Complicating BRCA2-Mutated Metastatic Prostate Cancer"],"prefix":"10.7759","author":[{"given":"Nidha","family":"Shapoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Izaguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Mattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Gotlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen S","year":"2015","unstructured":"Gillessen S, Omlin A, Attard G, et al.. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015, 26:1589-604. 10.1093\/annonc\/mdv257","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai MM","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, Gill IS. Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open. 2022, 5:e222246. 10.1001\/jamanetworkopen.2022.2246","journal-title":"JAMA Netw Open"},{"key":"ref3","article-title":"Resistance in prostate cancer: mechanisms, challenges and therapeutic innovations","volume":"31","author":"Shapoo N","year":"2024","unstructured":"Shapoo N, Shapoo N, Boma N, Gotlieb V. Resistance in prostate cancer: mechanisms, challenges and therapeutic innovations. J Clin Trials. 2024, 31:1.","journal-title":"J Clin Trials"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001570","article-title":"Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations","volume":"205","author":"Shore N","year":"2021","unstructured":"Shore N, Oliver L, Shui I, et al.. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. J Urol. 2021, 205:977-86. 10.1097\/JU.0000000000001570","journal-title":"J Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16712","article-title":"BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer","volume":"8","author":"Cui M","year":"2017","unstructured":"Cui M, Gao XS, Gu X, et al.. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer. Oncotarget. 2017, 8:40222-32. 10.18632\/oncotarget.16712","journal-title":"Oncotarget"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3577","article-title":"Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA","volume":"29","author":"Matsubara N","year":"2023","unstructured":"Matsubara N, de Bono J, Olmos D, et al.. Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA. Clin Cancer Res. 2023, 29:92-9. 10.1158\/1078-0432.CCR-21-3577","journal-title":"Clin Cancer Res"},{"key":"ref7","article-title":"Syndrome of inappropriate antidiuretic hormone secretion in a patient with hormone refractory prostate cancer","volume":"23","author":"Bogdanos J","year":"2003","unstructured":"Bogdanos J, Karamanolakis D, Milathianakis C, Koutsilieris M. Syndrome of inappropriate antidiuretic hormone secretion in a patient with hormone refractory prostate cancer. Anticancer Res. 2003, 23:1755-6.","journal-title":"Anticancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2001.00362.x","article-title":"Prostate adenocarcinoma producing syndrome of inappropriate secretion of antidiuretic hormone","volume":"8","author":"Yamazaki T","year":"2001","unstructured":"Yamazaki T, Suzuki H, Tobe T, et al.. Prostate adenocarcinoma producing syndrome of inappropriate secretion of antidiuretic hormone. Int J Urol. 2001, 8:513-6. 10.1046\/j.1442-2042.2001.00362.x","journal-title":"Int J Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2025.103148","article-title":"Dual paraneoplastic syndrome with prostate cancer: a case of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and humoral hypercalcemia of malignancy (HHM)","volume":"62","author":"Abe J","year":"2025","unstructured":"Abe J, Muranaka T, Kunishima Y. Dual paraneoplastic syndrome with prostate cancer: a case of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) and humoral hypercalcemia of malignancy (HHM). Urol Case Rep. 2025, 62:103148. 10.1016\/j.eucr.2025.103148","journal-title":"Urol Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep17010008","article-title":"Solid tumors, liquid challenges: the impact of coagulation disorders","volume":"17","author":"Shapoo N","year":"2025","unstructured":"Shapoo N, Boma N, Chaudhari S, Gotlieb V. Solid tumors, liquid challenges: the impact of coagulation disorders. Hematol Rep. 2025, 17:8. 10.3390\/hematolrep17010008","journal-title":"Hematol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic microangiopathy in oncology - a review","volume":"14","author":"Val\u00e9rio P","year":"2021","unstructured":"Val\u00e9rio P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol. 2021, 14:101081. 10.1016\/j.tranon.2021.101081","journal-title":"Transl Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5414\/CNCS110609","article-title":"Thrombotic microangiopathy secondary to recurrent prostate cancer","volume":"9","author":"Newton J","year":"2021","unstructured":"Newton J, Floyd L, Ponnusamy A, Anderton J. Thrombotic microangiopathy secondary to recurrent prostate cancer. Clin Nephrol Case Stud. 2021, 9:105-9. 10.5414\/CNCS110609","journal-title":"Clin Nephrol Case Stud"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.09.069","article-title":"Thrombotic microangiopathy in advanced prostatic carcinoma","volume":"63","author":"Biers SM","year":"2004","unstructured":"Biers SM, Sullivan ME, Roberts IS, Noble JG. Thrombotic microangiopathy in advanced prostatic carcinoma. Urology. 2004, 63:380-2. 10.1016\/j.urology.2003.09.069","journal-title":"Urology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0568-x","article-title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report","volume":"30","author":"Iams W","year":"2013","unstructured":"Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Med Oncol. 2013, 30:568. 10.1007\/s12032-013-0568-x","journal-title":"Med Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eucr.2019.101098","article-title":"Docetaxel chemotherapy temporarily improved pulmonary tumor thrombotic microangiopathy induced by prostate cancer secreting carcinoembryonic antigen and carbohydrate antigen 19-9: a case report","volume":"29","author":"Yu O","year":"2020","unstructured":"Yu O, Rikiya T, Yasuyuki M, Mikio S. Docetaxel chemotherapy temporarily improved pulmonary tumor thrombotic microangiopathy induced by prostate cancer secreting carcinoembryonic antigen and carbohydrate antigen 19-9: a case report. Urol Case Rep. 2020, 29:101098. 10.1016\/j.eucr.2019.101098","journal-title":"Urol Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/453714-syndrome-of-inappropriate-antidiuretic-hormone-secretion-and-thrombotic-microangiopathy-as-paraneoplastic-syndromes-complicating-brca2-mutated-metastatic-prostate-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:24:54Z","timestamp":1768076694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/453714-syndrome-of-inappropriate-antidiuretic-hormone-secretion-and-thrombotic-microangiopathy-as-paraneoplastic-syndromes-complicating-brca2-mutated-metastatic-prostate-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.101249","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,10]]}}}